Brain‐targeted Nano‐ERASER downregulates PD‐L1 for Alzheimer’s disease therapy

Since protein malfunction and neuroinflammation prevail in many CNS disease conditions, the success of BTN-PDL1 could also be beneficial for the treatment of AD, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, stroke, and traumatic brain injury.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70859_102249
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Brain‐targeted Nano‐ERASER downregulates PD‐L1 for Alzheimer’s disease therapy

Peisheng Xu
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

Brain‐targeted Nano‐ERASER downregulates PD‐L1 for Alzheimer’s disease therapy

Peisheng Xu
article en

Abstract

Since protein malfunction and neuroinflammation prevail in many CNS disease conditions, the success of BTN-PDL1 could also be beneficial for the treatment of AD, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, stroke, and traumatic brain injury.

Alzheimer s & DementiaVol. 21(S5)
University of South Carolina (US)
Openalex Percentile: Top 33%
Alzheimer's disease research and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Brain‐targeted Nano‐ERASER downregulates PD‐L1 for Alzheimer’s disease therapy — Peisheng Xu · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS